Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas

Medicine (United States)

Volumn 95, Issue 9, 2016, Pages

  Chen, Jun Rui ^a   Yao, Yu ^a   Xu, Hong Zhi ^a   Qin, Zhi Yong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TUMOR MARKER;

ARTICLE; BRAIN TUMOR; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COCHRANE LIBRARY; EMBASE; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; MEDLINE; META ANALYSIS; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84962526348     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002583     Document Type: Article

References (50)

1. Urbańska K, Sokołowska J, Szmidt M, et al. Glioblastoma multiforme: an overview. Contemp Oncol (Pozn). 2014;18:307-312.
2. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764-772.
3. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119:487-494.
4. Guo C, Pirozzi CJ, Lopez GY, et al. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol. 2011;24:648-652.
5. Alexander BM, Mehta MP. Role of isocitrate dehydrogenase in glioma. Expert Rev Neurother. 2011;11:1399-1409.
6. Koshland DE Jr, Walsh K, LaPorte DC. Sensitivity of metabolic fluxes to covalent control. Curr Top Cell Regul. 1985;27:13-22.
7. Geisbrecht BV, Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem. 1999;274:30527-30533.
8. Margittai E, Banhegyi G. Isocitrate dehydrogenase: A NADPHgenerating enzyme in the lumen of the endoplasmic reticulum. Arch Biochem Biophys. 2008;471:184-190.
9. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
10. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597-602.
11. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11:341-347.
12. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-474.
13. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597-1604.
14. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744.
15. Baldewpersad Tewarie NM, Burgers IA, Dawood Y, et al. NADP+dependent IDH1 R132 mutation and its relevance for glioma patient survival. Med Hypotheses. 2013;80:728-731.
16. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120:719-729.
17. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75:1560-1566.
18. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177:2708-2714.
19. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4154.
20. Nobusawa S, Watanabe T, Kleihues P. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15:6002-6007.
21. Mukasa A, Takayanagi S, Saito K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012;103:587-592.
22. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-W94.
23. Sullivan GM. Irb 101. J Grad Med Educ. 2011;3:5-6.
24. Moga C, Guo B, Schopflocher D, et al. Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique. Edmonton AB: Institute of Health Economics; 2012.
25. Yao Y, Chan AK, Qui ZY, et al. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival. PLoS One. 2013;8:e67421.
26. Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer. 2013;49:3477-3485.
27. Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol. 2012;110:325-333.
28. Okita Y, Narita Y, Miyakita Y, et al. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol. 2012;41:1325-1336.
29. Ohka F, Natsume A, Motomura K, et al. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One. 2011;6:e23332.
30. Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17:4588-4599.
31. Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol. 2012;109:15-22.
32. Takano S, Kato Y, Yamamoto T, et al. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol. 2012;108:361-373.
33. Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32: 783-790.
34. Hatanpaa KJ, Hu T, Vemireddy V, et al. High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. J Neurooncol. 2014;117:183-189.
35. Polivka J, Polivka J Jr, Rohan V, et al. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia. Biomed Res Int. 2014;2014:735659.
36. Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer. 2012;118:452-460.
37. Frenel JS, Leux C, Loussouarn D, et al. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: A single-center experience. J Neurooncol. 2013;114:85-91.
38. Ohno M, Narita Y, Miyakita Y, et al. Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lowergrade gliomas. Brain Tumor Pathol. 2013;30:224-232.
39. Leibetseder A, Ackerl M, Flechl B, et al. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: A study of the Society of Austrian Neurooncology (SANO). Neuro Oncol. 2013;15:112-121.
40. SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012;103:269-273.
41. SongTao Q, Yu L, Lu YT, et al. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep. 2011;26:1479-1485.
42. Christensen BC, Smith AA, Zheng S, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011;103:143-153.
43. Hodges TR, Choi BD, Bigner DD, et al. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: A review. J Neurosurg. 2013;118:1176-1180.
44. Hartmann C, Hentschel B, Simon M, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19:5146-5157.
45. Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 2014;16:1263-1273.
46. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81:1515-1522.
47. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2013;31:344-350.
48. Cairncross G, Wang M, Shaw E, et al. A phase 3 trial of chemoradiotherapy for anaplastic oligodendroglioma: long term results of RTOG 9402. J Clin Oncol. 2013;31:337-343.
49. Cheng HB, Yue W, Xie C, et al. IDH1 mutation is associated with improved overall survival in patients with glioblastoma: A metaanalysis. Tumour Biol. 2013;34:3555-3559.
50. Zou P, Xu H, Chen P, et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: A metaanalysis. PLoS One. 2013;8:e68782.